Immunotherapy of house dust mite allergy
House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergic skin diseases. Allergen specific immunotherapy (AIT) is the only potential disease-modifying treat...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2017-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_6171aebd6fdc46b3ac72fb23b6bebcc0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Lin Yang |e author |
| 700 | 1 | 0 | |a Rongfei Zhu |e author |
| 245 | 0 | 0 | |a Immunotherapy of house dust mite allergy |
| 260 | |b Taylor & Francis Group, |c 2017-10-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2017.1364823 | ||
| 520 | |a House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergic skin diseases. Allergen specific immunotherapy (AIT) is the only potential disease-modifying treatment of HDM allergic subjects. However, AIT remains underused due to no universally accepted allergen standardization and a shortage of rigorous clinical studies to confirm safety and efficacy. With the effort of doctors and researchers in allergy field, efficacy, safety, standardization and strategy of AIT are being continuously developed. This review presents the updated research based on recently published trials and meta-analyses. | ||
| 546 | |a EN | ||
| 690 | |a efficacy | ||
| 690 | |a house dust mite | ||
| 690 | |a immunotherapy | ||
| 690 | |a safety | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 13, Iss 10, Pp 2390-2396 (2017) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2017.1364823 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/6171aebd6fdc46b3ac72fb23b6bebcc0 |z Connect to this object online. |